Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)

    Summary
    EudraCT number
    		 2021-002844-66
    Trial protocol
    		 DE   AT   IT   ES   NL   HU   FR  
    Global end of trial date
    29 Apr 2024

    Results information
    Results version number
    		 v2(current)
    This version publication date
    30 Jan 2025
    First version publication date
    25 Oct 2024
    Other versions
    		 v1
    Version creation reason

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    INCB 50465-309
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Incyte Corporation
    Sponsor organisation address
    1801 Augustine Cutoff Drive, Wilmington, United States, 19803
    Public contact
    Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com
    Scientific contact
    Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 Apr 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Apr 2024
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The purpose of this study was to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA).
    Protection of trial subjects
    This study was to be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki (Brazil 2013) and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws and country-specific regulations, including WMO (Medical Research Involving Human Participants Act) and Clinical Trials Regulation (European Union) No. 536/2014, in which the study was being conducted.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    15 Mar 2022
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Austria: 2
    Country: Number of subjects enrolled
    Spain: 2
    Country: Number of subjects enrolled
    Italy: 1
    Country: Number of subjects enrolled
    Japan: 2
    Country: Number of subjects enrolled
    Poland: 5
    Country: Number of subjects enrolled
    United States: 1
    Worldwide total number of subjects
    13
    EEA total number of subjects
    10
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    7
    From 65 to 84 years
    6
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 This study was designed to evaluate parsaclisib 2.5 mg QD compared with placebo over a 24-week double-blind treatment period followed by a 24-week open-label treatment period with parsaclisib. Participants could then continue to receive parsaclisib in a long-term extension period.

    Period 1
    Period 1 title
    24-week Double-blind Treatment Period
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Monitor, Carer, Data analyst

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Parsaclisib
    Arm description
    		 Participants received parsaclisib 2.5 milligrams (mg) once daily (QD) for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for an additional 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years.
    Arm type
    		 Experimental

    Investigational medicinal product name
    parsaclisib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    2.5 mg QD

    Arm title
    		 Placebo followed by parsaclisib
    Arm description
    		 Participants received matching placebo QD for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years. Participants may have received parsaclisib before reaching Week 24.
    Arm type
    		 Experimental

    Investigational medicinal product name
    placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    2.5 mg QD

    Number of subjects in period 1
    		Parsaclisib Placebo followed by parsaclisib
    Started
    7
    6
    Completed
    4
    4
    Not completed
    3
    2
         Physician decision
    1
    -
         Consent withdrawn by subject
    -
    1
         Adverse event, non-fatal
    1
    -
         Study Terminated by Sponsor
    1
    1
    Period 2
    Period 2 title
    24-week Open-label Period
    Is this the baseline period?
    		 No
    Allocation method
    Non-randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Parsaclisib
    Arm description
    		 Participants received parsaclisib 2.5 milligrams (mg) once daily (QD) for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for an additional 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years.
    Arm type
    		 Experimental

    Investigational medicinal product name
    parsaclisib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    2.5 mg QD

    Arm title
    		 Placebo followed by parsaclisib
    Arm description
    		 Participants received matching placebo QD for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years. Participants may have received parsaclisib before reaching Week 24.
    Arm type
    		 Experimental

    Investigational medicinal product name
    parsaclisib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    2.5 mg QD

    Number of subjects in period 2
    		Parsaclisib Placebo followed by parsaclisib
    Started
    4
    4
    Completed
    2
    2
    Not completed
    2
    2
         Consent withdrawn by subject
    1
    -
         Adverse event, non-fatal
    1
    2
    Period 3
    Period 3 title
    Long-term Extension Period (~2 years)
    Is this the baseline period?
    		 No
    Allocation method
    Non-randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Parsaclisib
    Arm description
    		 Participants received parsaclisib 2.5 milligrams (mg) once daily (QD) for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for an additional 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years.
    Arm type
    		 Experimental

    Investigational medicinal product name
    parsaclisib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    2.5 mg QD

    Arm title
    		 Placebo followed by parsaclisib
    Arm description
    		 Participants received matching placebo QD for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years. Participants may have received parsaclisib before reaching Week 24.
    Arm type
    		 Experimental

    Investigational medicinal product name
    parsaclisib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    2.5 mg QD

    Number of subjects in period 3
    		Parsaclisib Placebo followed by parsaclisib
    Started
    2
    2
    Completed
    2
    2

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Parsaclisib
    Reporting group description
    		 Participants received parsaclisib 2.5 milligrams (mg) once daily (QD) for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for an additional 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years.

    Reporting group title
    Placebo followed by parsaclisib
    Reporting group description
    		 Participants received matching placebo QD for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years. Participants may have received parsaclisib before reaching Week 24.

    Reporting group values
    		 Parsaclisib Placebo followed by parsaclisib Total
    Number of subjects
    		 7 6 13
    Age categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0 0
        Children (2-11 years)
    		 0 0 0
        Adolescents (12-17 years)
    		 0 0 0
        Adults (18-64 years)
    		 3 4 7
        From 65-84 years
    		 4 2 6
        85 years and over
    		 0 0 0
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    		 62.3 ( 14.28 ) 57.8 ( 15.54 ) -
    Sex: Female, Male
    Units: participants
        Female
    		 4 6 10
        Male
    		 3 0 3
    Race/Ethnicity, Customized
    Units: Subjects
        White/Caucasian
    		 6 4 10
        Asian
    		 1 1 2
        Missing
    		 0 1 1
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    		 0 1 1
        Not Hispanic or Latino
    		 7 4 11
        Unknown or Not Reported
    		 0 1 1
    Subject analysis sets

    Subject analysis set title
    Placebo
    Subject analysis set type
    		 Full analysis
    Subject analysis set description
    Participants received matching placebo QD for 24 weeks during the double-blind treatment period.

    Subject analysis sets values
    		 Placebo
    Number of subjects
    6
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    4
        From 65-84 years
    2
        85 years and over
    0
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    ( )
    Sex: Female, Male
    Units: participants
        Female
        Male
    Race/Ethnicity, Customized
    Units: Subjects
        White/Caucasian
        Asian
        Missing
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
        Not Hispanic or Latino
        Unknown or Not Reported

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Parsaclisib
    Reporting group description
    		 Participants received parsaclisib 2.5 milligrams (mg) once daily (QD) for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for an additional 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years.

    Reporting group title
    Placebo followed by parsaclisib
    Reporting group description
    		 Participants received matching placebo QD for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years. Participants may have received parsaclisib before reaching Week 24.
    Reporting group title
    Parsaclisib
    Reporting group description
    		 Participants received parsaclisib 2.5 milligrams (mg) once daily (QD) for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for an additional 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years.

    Reporting group title
    Placebo followed by parsaclisib
    Reporting group description
    		 Participants received matching placebo QD for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years. Participants may have received parsaclisib before reaching Week 24.
    Reporting group title
    Parsaclisib
    Reporting group description
    		 Participants received parsaclisib 2.5 milligrams (mg) once daily (QD) for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for an additional 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years.

    Reporting group title
    Placebo followed by parsaclisib
    Reporting group description
    		 Participants received matching placebo QD for 24 weeks during the double-blind treatment period. Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment had the option of continuing into an open-label treatment period for 24 weeks of parsaclisib 2.5 mg QD, and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years. Participants may have received parsaclisib before reaching Week 24.

    Subject analysis set title
    Placebo
    Subject analysis set type
    		 Full analysis
    Subject analysis set description
    Participants received matching placebo QD for 24 weeks during the double-blind treatment period.

    Primary: Percentage of participants attaining a durable hemoglobin response

    		 Close Top of page
    End point title
    		 Percentage of participants attaining a durable hemoglobin response [1]
    End point description
    A durable hemoglobin response was defined as hemoglobin ≥10 grams per deciliter (g/dL) with an increase from Baseline of ≥2 g/dL not attributed to rescue therapy at ≥3 of the 4 available visits at Week 12 and/or later during the 24-week double-blind treatment period. Analysis was conducted in members of the Safety Analysis Set, comprised of all randomized participants who received at least 1 dose of study drug. Treatment groups were determined according to the actual treatment the participant received on Day 1 regardless of assigned study treatment.
    End point type
    Primary
    End point timeframe
    up to Week 24
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Statistical analysis was not conducted for this endpoint.
    End point values
    		 Parsaclisib Placebo followed by parsaclisib
    Number of subjects analysed
    3 [2]
    4 [3]
    Units: percentage of participants
        number (not applicable)
    33.3
    25.0
    Notes
    [2] - Safety Analysis Set. Only participants with available data were analyzed.
    [3] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Percentage of participants with a ≥3-point increase from Baseline in Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) score at Week 24

    		 Close Top of page
    End point title
    		 Percentage of participants with a ≥3-point increase from Baseline in Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) score at Week 24
    End point description
    The FACIT-F scale was developed to assess anemia-related fatigue. The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. A clinically meaningful change in the FACIT-F score was defined as ≥3-point increase from Baseline. Item scores range from 0 (“not at all”) to 4 (“very much”), and the total score ranges from 0 to 52; lower scores indicate greater fatigue. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
    End point type
    Secondary
    End point timeframe
    Baseline; Week 24
    End point values
    		 Parsaclisib Placebo followed by parsaclisib
    Number of subjects analysed
    3 [4]
    4 [5]
    Units: percentage of participants
        number (not applicable)
    66.7
    50.0
    Notes
    [4] - Safety Analysis Set. Only participants with available data were analyzed.
    [5] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Percentage of participants with a 50 meter increase from Baseline to Week 24 in a 6-minute walk test (6MWT)

    		 Close Top of page
    End point title
    		 Percentage of participants with a 50 meter increase from Baseline to Week 24 in a 6-minute walk test (6MWT)
    End point description
    The 6MWT is used to evaluate submaximal exercise capacity. It is a self-paced measurement of the distance that a participant can quickly walk on a flat, hard surface in a period of 6 minutes.
    End point type
    Secondary
    End point timeframe
    Baseline; Week 24
    End point values
    		 Parsaclisib Placebo followed by parsaclisib
    Number of subjects analysed
    2 [6]
    4 [7]
    Units: percentage of participants
        number (not applicable)
    100.0
    0.0
    Notes
    [6] - Safety Analysis Set. Only participants with available data were analyzed.
    [7] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Change from Baseline in the FACIT-F score at each post-Baseline visit

    		 Close Top of page
    End point title
    		 Change from Baseline in the FACIT-F score at each post-Baseline visit
    End point description
    The FACIT-F scale was developed to assess anemia-related fatigue. The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. A clinically meaningful change in the FACIT-F score was defined as ≥3-point increase from Baseline. Item scores range from 0 (“not at all”) to 4 (“very much”), and the total score ranges from 0 to 52; lower scores indicate greater fatigue. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. 8888=No participants were analyzed at this time point. 9999=Standard deviation cannot be calculated for a single participant. End of Treatment (EOT), Double-blind Period: assessment performed for participants who discontinued treatment before Week 24. EOT, Open-label Period: assessment performed for participants who discontinued treatment after Week 24 and before Week 56. Follow-up Visit 3 occurred 12 weeks after the EOT visit.
    End point type
    Secondary
    End point timeframe
    Baseline; Day 1; Weeks 8, 12, 16, 20, 24, 28, 32, 40, 48, 56, and every 16 weeks post-Week 56
    End point values
    		 Parsaclisib Placebo followed by parsaclisib Placebo
    Number of subjects analysed
    7 [8]
    4 [9]
    6 [10]
    Units: scores on a scale
    arithmetic mean (standard deviation)
        Baseline, n=7, 4, 6
    31.1 ( 7.78 )
    31.3 ( 5.12 )
    28.5 ( 5.96 )
        CFB at Week 8, n=5, 0, 5
    2.4 ( 7.16 )
    8888 ( 8888 )
    8.2 ( 5.63 )
        CFB at Week 12, n=5, 0, 5
    3.6 ( 8.56 )
    8888 ( 8888 )
    7.6 ( 6.58 )
        CFB at Week 16, n=5, 0, 4
    6.2 ( 7.36 )
    8888 ( 8888 )
    3.8 ( 5.91 )
        CFB at Week 20, n=2, 0, 4
    4.5 ( 7.78 )
    8888 ( 8888 )
    2.0 ( 9.09 )
        CFB at Week 24, n=3, 0, 4
    5.0 ( 5.20 )
    8888 ( 8888 )
    3.3 ( 2.63 )
        CFB at EOT, Double-blind Period, n=2, 0, 1
    -8.0 ( 9.90 )
    8888 ( 8888 )
    20.0 ( 9999 )
        CFB at Week 28, n=1, 4, 0
    6.0 ( 9999 )
    6.5 ( 6.86 )
    8888 ( 8888 )
        CFB at Week 32, n=1, 3, 0
    -1.0 ( 9999 )
    -9.0 ( 13.89 )
    8888 ( 8888 )
        CFB at Week 40, n=0, 1, 0
    8888 ( 8888 )
    1.0 ( 9999 )
    8888 ( 8888 )
        CFB at Week 48, n=0, 1, 0
    8888 ( 8888 )
    5.0 ( 9999 )
    8888 ( 8888 )
        CFB at EOT, Open-label Period, n=1, 1, 0
    8.0 ( 9999 )
    -2.0 ( 9999 )
    8888 ( 8888 )
        CFB at Week 56, n=0, 1, 0
    8888 ( 8888 )
    1.0 ( 9999 )
    8888 ( 8888 )
        CFB at EOT, Long-term Extension Period, n=0, 1, 0
    8888 ( 8888 )
    1.0 ( 9999 )
    8888 ( 8888 )
        CFB at Follow-up Visit 3, n=2, 1, 0
    -1.0 ( 2.83 )
    0.0 ( 9999 )
    8888 ( 8888 )
    Notes
    [8] - Safety Analysis Set. Only participants with available data were analyzed.
    [9] - Safety Analysis Set. Only participants with available data were analyzed.
    [10] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Percentage change from Baseline in the FACIT-F score at each post-Baseline visit

    		 Close Top of page
    End point title
    		 Percentage change from Baseline in the FACIT-F score at each post-Baseline visit
    End point description
    The FACIT-F scale was developed to assess anemia-related fatigue. The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. A clinically meaningful change in the FACIT-F score was defined as ≥3-point increase from Baseline. Item scores range from 0 (“not at all”) to 4 (“very much”), and the total score ranges from 0 to 52; lower scores indicate greater fatigue. Percentage change from Baseline was calculated as ([the post-Baseline value minus the Baseline value]/Baseline value) x 100. 8888=No participants were analyzed at this time point. 9999=Standard deviation cannot be calculated for a single participant. End of Treatment (EOT), Double-blind Period: assessment performed for participants who discontinued treatment before Week 24. EOT, Open-label Period: assessment performed for participants who discontinued treatment after Week 24 and before Week 56. Follow-up Visit 3=12 weeks after the EOT visit.
    End point type
    Secondary
    End point timeframe
    Baseline; Day 1; Weeks 8, 12, 16, 20, 24, 28, 32, 40, 48, 56, and every 16 weeks post-Week 56
    End point values
    		 Parsaclisib Placebo followed by parsaclisib Placebo
    Number of subjects analysed
    7 [11]
    4 [12]
    6 [13]
    Units: percent change
    arithmetic mean (standard deviation)
        Week 8, n=5, 0, 5
    8.2 ( 21.25 )
    8888 ( 8888 )
    29.6 ( 21.40 )
        Week 12, n=5, 0, 5
    15.3 ( 32.05 )
    8888 ( 8888 )
    28.1 ( 26.10 )
        Week 16, n=5, 0, 4
    21.9 ( 27.65 )
    8888 ( 8888 )
    12.4 ( 20.21 )
        Week 20, n=2, 0, 4
    12.8 ( 24.79 )
    8888 ( 8888 )
    9.1 ( 31.07 )
        Week 24, n=3, 0, 4
    14.8 ( 16.97 )
    8888 ( 8888 )
    10.1 ( 6.71 )
        EOT, Double-blind Period, n=2, 0, 1
    -32.4 ( 42.62 )
    8888 ( 8888 )
    95.2 ( 9999 )
        Week 28, n=1, 4, 0
    18.8 ( 9999 )
    22.6 ( 26.80 )
    8888 ( 8888 )
        Week 32, n=1, 3, 0
    -4.8 ( 9999 )
    -26.9 ( 40.55 )
    8888 ( 8888 )
        Week 40, n=0, 1, 0
    8888 ( 8888 )
    2.9 ( 9999 )
    8888 ( 8888 )
        Week 48, n=0, 1, 0
    8888 ( 8888 )
    14.7 ( 9999 )
    8888 ( 8888 )
        EOT, Open-label Period, n=1, 1, 0
    25.0 ( 9999 )
    -5.4 ( 9999 )
    8888 ( 8888 )
        Week 56, n=0, 1, 0
    8888 ( 8888 )
    2.9 ( 9999 )
    8888 ( 8888 )
        EOT, Long-term Extension Period, n=0, 1, 0
    8888 ( 8888 )
    2.96 ( 9999 )
    8888 ( 8888 )
        Follow-up Visit 3, n=2, 1, 0
    -5.1 ( 10.41 )
    0.0 ( 9999 )
    8888 ( 8888 )
    Notes
    [11] - Safety Analysis Set. Only participants with available data were analyzed.
    [12] - Safety Analysis Set. Only participants with available data were analyzed.
    [13] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Change from Baseline in hemoglobin at each post-Baseline visit

    		 Close Top of page
    End point title
    		 Change from Baseline in hemoglobin at each post-Baseline visit
    End point description
    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. 8888= No participants were analyzed at this time point. 9999=Standard deviation cannot be calculated for this for a single participant. End of Treatment (EOT), Double-blind Period: assessment performed for participants who discontinued treatment before Week 24. EOT, Open-label Period: assessment performed for participants who discontinued treatment after Week 24 and before Week 56. Follow-up Visits 1, 2, and 3 occurred 4, 8, and 12 weeks, respectively, after the EOT visit.
    End point type
    Secondary
    End point timeframe
    Baseline; Day 1; Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, and every 8 weeks post-Week 56
    End point values
    		 Parsaclisib Placebo followed by parsaclisib Placebo
    Number of subjects analysed
    7 [14]
    4 [15]
    6 [16]
    Units: grams per liter
    arithmetic mean (standard deviation)
        Baseline, n=7, 4, 6
    98.4 ( 21.53 )
    85.3 ( 12.97 )
    86.5 ( 15.31 )
        CFB at Week 2, n=7, 0, 6
    8.7 ( 11.78 )
    8888 ( 8888 )
    -9.3 ( 29.09 )
        CFB at Week 4, n=6, 0, 5
    14.2 ( 13.14 )
    8888 ( 8888 )
    -4.4 ( 14.29 )
        CFB at Week 6, n=7, 0, 4
    14.3 ( 16.83 )
    8888 ( 8888 )
    2.7 ( 6.38 )
        CFB at Week 8, n=5, 0, 5
    15.0 ( 18.95 )
    8888 ( 8888 )
    12.7 ( 14.07 )
        CFB at Week 10, n=6, 0, 4
    16.5 ( 16.32 )
    8888 ( 8888 )
    16.5 ( 17.41 )
        CFB at Week 12, n=6, 0, 5
    20.5 ( 11.01 )
    8888 ( 8888 )
    13.8 ( 19.69 )
        CFB at Week 16, n=5, 0, 4
    22.4 ( 16.41 )
    8888 ( 8888 )
    19.5 ( 15.76 )
        CFB at Week 20, n=3, 0, 4
    7.7 ( 1.53 )
    8888 ( 8888 )
    15.3 ( 6.08 )
        CFB at Week 24, n=3, 0, 4
    19.3 ( 22.28 )
    8888 ( 8888 )
    19.5 ( 14.80 )
        CFB at EOT, Double-blind Period, n=1, 0, 1
    11.0 ( 9999 )
    8888 ( 8888 )
    -62.4 ( 9999 )
        CFB at Week 26, n=3, 3, 0
    3.0 ( 24.33 )
    14.0 ( 9.60 )
    8888 ( 8888 )
        CFB at Week 28, n=4, 4, 0
    8.3 ( 26.48 )
    18.9 ( 19.58 )
    8888 ( 8888 )
        CFB at Week 30, n=1, 2, 0
    27.0 ( 9999 )
    8.10 ( 32.67 )
    8888 ( 8888 )
        CFB at Week 32, n=2, 3, 0
    26.0 ( 11.31 )
    19.0 ( 31.32 )
    8888 ( 8888 )
        CFB at Week 36, n=2, 3, 0
    18.5 ( 13.44 )
    22.8 ( 18.01 )
    8888 ( 8888 )
        CFB at Week 40, n=2, 2, 0
    26.5 ( 7.78 )
    21.5 ( 12.02 )
    8888 ( 8888 )
        CFB at Week 44, n=2, 2, 0
    27.5 ( 14.85 )
    25.0 ( 21.21 )
    8888 ( 8888 )
        CFB at Week 48, n=1, 2, 0
    32.0 ( 9999 )
    22.5 ( 21.92 )
    8888 ( 8888 )
        CFB at EOT, Open-label Period, n=1, 1, 0
    124.0 ( 9999 )
    127.7 ( 9999 )
    8888 ( 8888 )
        CFB at Week 56, n=1, 2, 0
    36.0 ( 9999 )
    17.5 ( 12.02 )
    8888 ( 8888 )
        CFB at Week 64, n=0, 1, 0
    8888 ( 8888 )
    8.0 ( 9999 )
    8888 ( 8888 )
        CFB at EOT, Long-term Extension Period, n=0, 1, 0
    8888 ( 8888 )
    86.0 ( 9999 )
    8888 ( 8888 )
        CFB at Follow-up Visit 1, n=4, 1, 0
    11.0 ( 7.62 )
    40.0 ( 9999 )
    8888 ( 8888 )
        CFB at Follow-up Visit 2, n=4, 1, 0
    12.5 ( 17.52 )
    32.0 ( 9999 )
    8888 ( 8888 )
        CFB at Follow-up Visit 3, n=6, 1, 0
    20.3 ( 9.95 )
    23.0 ( 9999 )
    8888 ( 8888 )
    Notes
    [14] - Safety Analysis Set. Only participants with available data were analyzed.
    [15] - Safety Analysis Set. Only participants with available data were analyzed.
    [16] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Percentage change from Baseline in hemoglobin at each post-Baseline visit

    		 Close Top of page
    End point title
    		 Percentage change from Baseline in hemoglobin at each post-Baseline visit
    End point description
    Percentage change from Baseline was calculated as ([the post-Baseline value minus the Baseline value]/Baseline value) x 100. 8888= No participants were analyzed at this time point. 9999=Standard deviation cannot be calculated for this for a single participant. End of Treatment (EOT), Double-blind Period: assessment performed for participants who discontinued treatment before Week 24. EOT, Open-label Period: assessment performed for participants who discontinued treatment after Week 24 and before Week 56. Follow-up Visits 1, 2, and 3 occurred 4, 8, and 12 weeks, respectively, after the EOT visit.
    End point type
    Secondary
    End point timeframe
    Baseline; Day 1; Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, and every 8 weeks post-Week 56
    End point values
    		 Parsaclisib Placebo followed by parsaclisib Placebo
    Number of subjects analysed
    7 [17]
    4 [18]
    6 [19]
    Units: percent change
    arithmetic mean (standard deviation)
        Week 2, n=7, 0, 6
    8.2 ( 13.82 )
    8888 ( 8888 )
    -12.3 ( 41.18 )
        Week 4, n=6, 0, 5
    14.2 ( 13.68 )
    8888 ( 8888 )
    -3.5 ( 16.87 )
        Week 6, n=7, 0, 4
    14.2 ( 18.21 )
    8888 ( 8888 )
    3.4 ( 7.42 )
        Week 8, n=5, 0, 5
    14.3 ( 19.65 )
    8888 ( 8888 )
    14.0 ( 14.59 )
        Week 10, n=6, 0, 4
    16.5 ( 17.59 )
    8888 ( 8888 )
    17.8 ( 17.44 )
        Week 12, n=6, 0, 5
    20.7 ( 12.36 )
    8888 ( 8888 )
    13.6 ( 21.15 )
        Week 16, n=5, 0, 4
    23.2 ( 17.81 )
    8888 ( 8888 )
    21.7 ( 16.02 )
        Week 20, n=3, 0, 4
    7.6 ( 2.11 )
    8888 ( 8888 )
    18.5 ( 9.32 )
        Week 24, n=3, 0, 4
    19.4 ( 22.70 )
    8888 ( 8888 )
    22.7 ( 15.52 )
        CFB at EOT, Double-blind Period, n=1, 0, 1
    12.0 ( 9999 )
    8888 ( 8888 )
    -87.9 ( 9999 )
        Week 26, n=3, 3, 0
    3.4 ( 24.52 )
    15.2 ( 9.34 )
    8888 ( 8888 )
        Week 28, n=4, 4, 0
    9.7 ( 27.56 )
    23.4 ( 25.16 )
    8888 ( 8888 )
        Week 30, n=1, 2, 0
    30.0 ( 9999 )
    6.6 ( 36.17 )
    8888 ( 8888 )
        Week 32, n=2, 3, 0
    29.0 ( 12.41 )
    23.6 ( 40.57 )
    8888 ( 8888 )
        Week 36, n=2, 3, 0
    20.6 ( 14.85 )
    29.3 ( 26.69 )
    8888 ( 8888 )
        Week 40, n=2, 2, 0
    29.6 ( 8.46 )
    29.7 ( 18.67 )
    8888 ( 8888 )
        Week 44, n=2, 2, 0
    30.7 ( 16.35 )
    34.9 ( 31.46 )
    8888 ( 8888 )
        Week 48, n=1, 2, 0
    35.6 ( 9999 )
    31.6 ( 32.12 )
    8888 ( 8888 )
        CFB at EOT, Open-label Period, n=1, 1, 0
    25.3 ( 9999 )
    31.7 ( 9999 )
    8888 ( 8888 )
        Week 56, n=1, 2, 0
    40.0 ( 9999 )
    24.3 ( 18.21 )
    8888 ( 8888 )
        Week 64, n=0, 1, 0
    8888 ( 8888 )
    10.1 ( 9999 )
    8888 ( 8888 )
        CFB at EOT, Long-term Extension Period, n=0, 1, 0
    8888 ( 8888 )
    8.9 ( 9999 )
    8888 ( 8888 )
        Follow-up Visit 1, n=4, 1, 0
    11.5 ( 8.19 )
    41.2 ( 9999 )
    8888 ( 8888 )
        Follow-up Visit 2, n=4, 1, 0
    14.5 ( 19.47 )
    33.0 ( 9999 )
    8888 ( 8888 )
        Follow-up Visit3, n=6, 1, 0
    23.4 ( 13.52 )
    23.7 ( 9999 )
    8888 ( 8888 )
    Notes
    [17] - Safety Analysis Set. Only participants with available data were analyzed.
    [18] - Safety Analysis Set. Only participants with available data were analyzed.
    [19] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Percentage of participants who received transfusions from Week 6 to Week 24 and from Week 24 to Week 48

    		 Close Top of page
    End point title
    		 Percentage of participants who received transfusions from Week 6 to Week 24 and from Week 24 to Week 48
    End point description
    Transfusion was permitted as a rescue treatment. Rescue medication was to be considered if the absolute hemoglobin level continued to decline, there was a > 1 g/dL decrease in hemoglobin from the prior assessment, or the participant developed new or worsening symptoms of warm autoimmune hemolytic anemia (wAIHA). 8888=No participants were analyzed at this time point.
    End point type
    Secondary
    End point timeframe
    Week 6 to Week 24; Week 24 to Week 48
    End point values
    		 Parsaclisib Placebo followed by parsaclisib Placebo
    Number of subjects analysed
    7 [20]
    4 [21]
    6 [22]
    Units: percentage of participants
    number (not applicable)
        Week 6 to Week 24, n=7, 0, 5
    42.9
    8888
    0.0
        Week 24 to Week 48, n=4, 4, 0
    25.0
    25.0
    8888
    Notes
    [20] - Safety Analysis Set. Only participants with available data were analyzed.
    [21] - Safety Analysis Set. Only participants with available data were analyzed.
    [22] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Change from Baseline in daily corticosteroid dose at Week 24

    		 Close Top of page
    End point title
    		 Change from Baseline in daily corticosteroid dose at Week 24
    End point description
    A new or increased dose of corticosteroids (prednisone or equivalent) from the Day 1 dose was permitted as rescue treatment. Rescue medication was to be considered if the absolute hemoglobin level continued to decline, there was a > 1 g/dL decrease in hemoglobin from the prior assessment, or the participant developed new or worsening symptoms of wAIHA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
    End point type
    Secondary
    End point timeframe
    Baseline; Week 24
    End point values
    		 Parsaclisib Placebo followed by parsaclisib
    Number of subjects analysed
    6 [23]
    3 [24]
    Units: milligrams
    arithmetic mean (standard deviation)
        Baseline, n=6, 3
    20.8 ( 10.21 )
    13.3 ( 5.77 )
        Change from Baseline at Week 24, n=5, 3
    -4.8 ( 10.41 )
    8.1 ( 14.02 )
    Notes
    [23] - Safety Analysis Set. Only participants with available data were analyzed.
    [24] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Percentage change from Baseline in daily corticosteroid dose at Week 24

    		 Close Top of page
    End point title
    		 Percentage change from Baseline in daily corticosteroid dose at Week 24
    End point description
    A new or increased dose of corticosteroids (prednisone or equivalent) from the Day 1 dose was permitted as rescue treatment. Rescue medication was to be considered if the absolute hemoglobin level continued to decline, there was a > 1 g/dL decrease in hemoglobin from the prior assessment, or the participant developed new or worsening symptoms of wAIHA. Percentage change from Baseline was calculated as ([the post-Baseline value minus the Baseline value]/Baseline value) x 100.
    End point type
    Secondary
    End point timeframe
    Baseline; Week 24
    End point values
    		 Parsaclisib Placebo followed by parsaclisib
    Number of subjects analysed
    5 [25]
    3 [26]
    Units: percent change
        arithmetic mean (standard deviation)
    -22.0 ( 60.07 )
    81.0 ( 140.21 )
    Notes
    [25] - Safety Analysis Set. Only participants with available data were analyzed.
    [26] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Percentage of participants who required rescue therapy at any visit from Week 6 through Week 24, and from Week 24 to Week 48

    		 Close Top of page
    End point title
    		 Percentage of participants who required rescue therapy at any visit from Week 6 through Week 24, and from Week 24 to Week 48
    End point description
    Rescue medication was to be considered if the absolute hemoglobin level continued to decline, there was a > 1 g/dL decrease in hemoglobin from the prior assessment, or the participant developed new or worsening symptoms of wAIHA. 8888=No participants were analyzed at this time point.
    End point type
    Secondary
    End point timeframe
    Week 6 to Week 24; Week 24 to Week 48
    End point values
    		 Parsaclisib Placebo followed by parsaclisib Placebo
    Number of subjects analysed
    7 [27]
    4 [28]
    5 [29]
    Units: percentage of participants
    number (not applicable)
        Week 6 to Week 24, n=7, 0, 5
    0.0
    8888
    0.0
        Week 24 to Week 48, n=4, 4, 0
    20.0
    0.0
    8888
    Notes
    [27] - Safety Analysis Set. Only participants with available data were analyzed.
    [28] - Safety Analysis Set. Only participants with available data were analyzed.
    [29] - Safety Analysis Set. Only participants with available data were analyzed.
    No statistical analyses for this end point

    Secondary: Number of participants with any ≥Grade 3 TEAE

    		 Close Top of page
    End point title
    		 Number of participants with any ≥Grade 3 TEAE
    End point description
    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. TEAEs were defined as AEs reported for the first time or the worsening of pre-existing events after the first dose of study drug. The severity of AEs were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
    End point type
    Secondary
    End point timeframe
    up to 446 days
    End point values
    		 Parsaclisib Placebo followed by parsaclisib Placebo
    Number of subjects analysed
    7 [30]
    4 [31]
    6 [32]
    Units: participants
    6
    3
    1
    Notes
    [30] - Safety Analysis Set
    [31] - Safety Analysis Set
    [32] - Safety Analysis Set
    No statistical analyses for this end point

    Secondary: Number of participants with any treatment-emergent adverse event (TEAE)

    		 Close Top of page
    End point title
    		 Number of participants with any treatment-emergent adverse event (TEAE)
    End point description
    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. TEAEs were defined as AEs reported for the first time or the worsening of pre-existing events after the first dose of study drug.
    End point type
    Secondary
    End point timeframe
    up to 446 days
    End point values
    		 Parsaclisib Placebo followed by parsaclisib Placebo
    Number of subjects analysed
    7 [33]
    4 [34]
    6 [35]
    Units: participants
    7
    4
    4
    Notes
    [33] - Safety Analysis Set
    [34] - Safety Analysis Set
    [35] - Safety Analysis Set
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    up to 446 days
    Adverse event reporting additional description
    For safety analysis, participants who transitioned from treatment with placebo to treatment with parsaclisib 2.5 milligrams (mg) once daily (QD) in the the open-label treatment period and the long-term extension period have been counted both in the placebo arm and the parsaclisib arm.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    22
    Reporting groups
    Reporting group title
    Parsaclisib
    Reporting group description
    		 Participants who completed the double-blind treatment period, tolerated study treatment, and, in the investigator's opinion, benefited from treatment continued into the open-label treatment period for 24 weeks of parsaclisib 2.5 mg QD and then the long-term extension period to receive parsaclisib 2.5 mg QD for up to 2 years.

    Reporting group title
    Placebo
    Reporting group description
    		 Participants received matching placebo once daily (QD) for 24 weeks during the double-blind treatment period.

    Serious adverse events
    		 Parsaclisib Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    6 / 11 (54.55%)
    0 / 6 (0.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Investigations
    Haemoglobin decreased
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Colitis
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Immune-mediated enterocolitis
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Urinary tract infection
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Parsaclisib Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    10 / 11 (90.91%)
    4 / 6 (66.67%)
    Vascular disorders
    Embolism
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Hot flush
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    0 / 11 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    3
    Influenza like illness
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Oedema
         subjects affected / exposed
    1 / 11 (9.09%)
    1 / 6 (16.67%)
         occurrences all number
    1
    1
    Oedema peripheral
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Catarrh
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Cough
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Dyspnoea
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    2 / 11 (18.18%)
    1 / 6 (16.67%)
         occurrences all number
    2
    1
    Mood altered
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    2 / 11 (18.18%)
    0 / 6 (0.00%)
         occurrences all number
    3
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Blood potassium decreased
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    C-reactive protein increased
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Neutrophil count decreased
         subjects affected / exposed
    2 / 11 (18.18%)
    0 / 6 (0.00%)
         occurrences all number
    2
    0
    Injury, poisoning and procedural complications
    Skin abrasion
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Nervous system disorders
    Amnesia
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Headache
         subjects affected / exposed
    2 / 11 (18.18%)
    2 / 6 (33.33%)
         occurrences all number
    3
    2
    Blood and lymphatic system disorders
    Lymphopenia
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Constipation
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Diarrhoea
         subjects affected / exposed
    3 / 11 (27.27%)
    0 / 6 (0.00%)
         occurrences all number
    3
    0
    Abdominal pain lower
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Faeces soft
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Flatulence
         subjects affected / exposed
    2 / 11 (18.18%)
    0 / 6 (0.00%)
         occurrences all number
    2
    0
    Gastritis
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Haemorrhoidal haemorrhage
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Erythema
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Rash erythematous
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Pruritus
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Renal and urinary disorders
    Choluria
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Dysuria
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Micturition disorder
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    2
    Myalgia
         subjects affected / exposed
    1 / 11 (9.09%)
    1 / 6 (16.67%)
         occurrences all number
    1
    1
    Infections and infestations
    COVID-19
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Cytomegalovirus infection
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Pneumonia
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Respiratory tract infection
         subjects affected / exposed
    2 / 11 (18.18%)
    0 / 6 (0.00%)
         occurrences all number
    3
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    0 / 11 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Hyperglycaemia
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Iron overload
         subjects affected / exposed
    1 / 11 (9.09%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    18 Aug 2022
    The primary purpose of the amendment was to incorporate feedback from advisory board members, which included the addition of a long-term extension for continued access to parscalisib, and to include prior Protocol Administrative Changes. This amendment also included the changes from local adaptations for Germany and France.
    10 May 2023
    The primary purpose of the amendment was to reduce or eliminate protocol-required procedures and visits due to closure of study enrollment.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 09:35:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA